The first and the second types of diabetes mellitus, autoimmune and non-autoimmune thyroiditis differential diagnosis possibility using the calculated index based on plasma butyrylcholinesterase isoforms activity

Abstract

BACKGROUND: The possibility of using a diagnostic index based on the use of blood plasma objective indicators to differentiate the diagnosis of type 1 and type 2 diabetes mellitus, autoimmune and non-autoimmune thyroiditis is an urgent task for timely decision-making on the use of a particular type of therapy, taking into account the etiology of a particular pathology. Changing the ratio of blood plasma butyrylcholinesterase isoforms activity makes it possible to identify increased excitability, to separate them among themselves depending on the genesis, and during treatment, to assess the activity of diseases and the effectiveness of therapeutic measures.

AIM: To develop a calculated diagnostic index for the differential diagnosis of diabetes and thyroiditis autoimmune type from symptomatically similar non-autoimmune pathologies, using the ratio of the plasma pseudocholinesterase isoforms activities.

MATERIALS AND METHODS: The study involved 188 people: 45 patients diagnosed with type 1 diabetes; 60 patients diagnosed with type 2 diabetes; 25 patients diagnosed with autoimmune thyroiditis; 25 patients with non-autoimmune thyroiditis; the control group consisted of 33 healthy volunteers. The groups were aligned by gender and age. Patients of all groups were examined by an endocrinologist and a therapeutist. The diagnoses were made in accordance with the Clinical Guidelines of the Russian Endocrinologists Association for the Diagnosis and Treatment of Autoimmune Thyroiditis in Adults, as well as the Clinical Guidelines “Type 1 Diabetes Mellitus in Adults”. In the blood plasma of all patients’ groups, the activity of pseudocholinesterase (butyrylcholinesterase) forms was determined by analysis using a modification of the Ellman’s method in combination with inhibitory analysis. The index was calculated based on the ratio of the studied enzyme typical and atypical forms activities. Based on the results of data analysis for all examined groups, diagnostic intervals were determined that are characteristic for each diagnosis, as well as for conditionally healthy people. Comparison of the patients distribution by categories of diagnosis was carried out using the Χ-square test with Yates correction in the SPSS 22 statistical software package.

RESULTS: The results of the blood plasma analysis determined that in the diagnoses of autoimmune thyroiditis and type 1 diabetes mellitus, there was an increase in the activity of increased activity of the butyrylcholinesterase isoform, while the activity of the atypical form remains more stable. The ratio of these forms was taken as the basis for the development of the calculated diagnostic index. Diagnostic index for the control group in the range of 1–2; for patients with non-autoimmune thyroiditis — 2,1–2,9; autoimmune thyroiditis — 3–3,5; type 1 diabetes mellitus — 3,6–5; type 2 diabetes — 0–1. Statistical analysis of the data showed that the diagnosis based on the index obtained in this way does not inferior to the diagnostic scales in terms of sensitivity and specificity. The findings are consistent with the evolution of data supporting each diagnosis.

CONCLUSIONS: The calculated index on the basis of butyrylcholinesterase activity is a promising, minimally invasive, fast and budgetary method, revealing a pronounced severity of occurrence in terms of symptoms, but different in etiology, type 1 diabetes mellitus and type 2 diabetes mellitus, autoimmune thyroiditis and thyroiditis of a non-autoimmune nature, which is of critical importance when choosing a therapeutic strategy and improving the quality of life of patients.

Keywords

autoimmune thyroiditis / non-autoimmune thyroiditis / type 1 diabetes mellitus / type 2 diabetes mellitus / butyrylcholinesterase / blood plasma / biomarker / isoforms / calculated index

References

[1] Dedov II, Shestakova MV, Vikulova OK, et al. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes mellitus. 2021;24(3):204–221. (In Russ.) DOI: 10.14341/DM12759

[2] Дедов И.И., Шестакова М.В., Викулова О.К. и др. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021 // Сахарный диабет. 2021. Т. 24, № 3. С. 204–221. DOI: 10.14341/DM12759

[3] Alessandri C, Conti F, Conigliaro P, et al. Seronegative autoimmune diseases. Ann NY Acad Sci. 2009;1173(1):52–59. DOI: 10.1111/j.1749-6632.2009.04806.x

[4] Alessandri C., Conti F., Conigliaro P. et al. Seronegative autoimmune diseases // Ann. N.Y. Acad. Sci. 2009, Vol. 1173, No. 1. P. 52–59. DOI: 10.1111/j.1749-6632.2009.04806.x

[5] Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000;405(6785):458–462. DOI: 10.1038/35013070

[6] Borovikova L.V., IvanovaS., Zhang M. et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin // Nature. 2000. Vol. 405, No. 6785. P. 458–462. DOI: 10.1038/35013070

[7] Chasset F, Richez C, Martin T, et al. Rare diseases that mimic Systemic Lupus Erythematosus (Lupus mimickers). Joint Bone Spine. 2019;86(2):165–171. DOI: 10.1016/j.jbspin.2018.10.007

[8] Chasset F., Richez. C., Martin T. et al. Rare diseases that mimic Systemic Lupus Erythematosus (Lupus mimickers) // Joint Bone Spine. 2019. Vol. 86, No. 2. P. 165–171. DOI: 10.1016/j.jbspin.2018.10.007

[9] Marks M, Marks JL. Viral arthritis. Clin Med (Lond). 2016;16(2):129–134. DOI: 10.7861/clinmedicine.16-2-129

[10] Marks M., Marks J.L. Viral arthritis // Clin. Med. (Lond). 2016. Vol. 16, No. 2. P. 129–134. DOI: 10.7861/clinmedicine.16-2-129

[11] Lockridge O. Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. Pharmacol Ther. 2015;148:34–46. DOI: 10.1016/j.pharmthera.2014.11.011

[12] Lockridge O. Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses // Pharmacol. Ther. 2015. Vol. 148. P. 34–46. DOI: 10.1016/j.pharmthera.2014.11.011

[13] Masson P., Lockridge O. Butyrylcholinesterase for protection from organophosphorus poisons: catalytic complexities and hysteretic behavior. Arch Biochem Biophys. 2010. Vol. 494, No. 2. P. 107–120. DOI: 10.1016/j.abb.2009.12.005

[14] Masson P., Lockridge O. Butyrylcholinesterase for protection from organophosphorus poisons: catalytic complexities and hysteretic behavior // Arch. Biochem. Biophys. 2010. Vol. 494, No. 2. P. 107–120. DOI: 10.1016/j.abb.2009.12.005

[15] Dedov II, Melnichenko GA, Gerasimov GA, et al. Clinical recommendations of the Russian Association of Endocrinologists for the diagnosis and treatment of autoimmune thyroiditis in adults. Problems of Endocrinology. 2003;49(6):50. (In Russ.) DOI: 10.14341/probl11777

[16] Дедов И.И., Мельниченко Г.А., Герасимов Г.А. и др. Клинические рекомендации Российской ассоциации эндокринологов по диагностике и лечению аутоиммунного тиреоидита у взрослых // Проблемы Эндокринологии. 2003. Т. 49, № 6. С. 50. DOI: 10.14341/probl11777

[17] Dedov II, Shestakova MV, Mayorov AY, et al. Diabetes mellitus type 1 in adults. Diabetes mellitus. 2020;23(1S):42–114. (In Russ.) DOI: 10.14341/DM12505

[18] Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Сахарный диабет 1-го типа у взрослых // Сахарный диабет. 2020. Т. 23, № 1S. С. 42–114. DOI: 10.14341/DM12505

[19] Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961;7(2):88–95. DOI: 10.1016/0006-2952(61)90145-9

[20] Ellman G.L., Courtney K.D., Andres V.Jr., Feather-Stone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity // Biochem. Pharmacol. 1961. Vol. 7, No. 2. P. 88–95. DOI: 10.1016/0006-2952(61)90145-9

[21] Patent RUS No. 2018000042/04.03.2018. Vasilev DS, Kozlova DI, Popov AV. Method for differential diagnosis of early or severe stage of rheumatoid arthritis with osteoarthritis. (In Russ.)

[22] Патент РФ на изобретение № 2018000042/04.03.2018. Васильев Д.С., Козлова Д.И., Попов А.В. Способ дифференциальной диагностики ранней или выраженной стадии ревматоидного артрита с остеоартритом.

[23] Wessler I, Kirkpatrick CJ. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br J Pharmacol. 2008;154(8):1558–1571. DOI: 10.1038/bjp.2008.185

[24] Wessler I., Kirkpatrick C.J. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans // Br. J. Pharmacol. 2008. Vol. 154, No. 8. P. 1558–1571. DOI: 10.1038/bjp.2008.185

[25] Das UN. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation Med Sci Monit. 2007;13(12):RA214–221. DOI: 10.1016/S1665-2681(19)30940-8

[26] Das U.N. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation // Med. Sci. Monit. 2007. Vol. 13, No. 12. P. RA214–221. DOI: 10.1016/S1665-2681(19)30940-8

[27] Grando SA, Kawashima K, Wessler I. Introduction: the non-neuronal cholinergic system in humans. Life Sci. 2003;72:2009–2012. DOI: 10.1016/s0024-3205(03)00063-8

[28] Grando S.A., Kawashima K., Wessler I. Introduction: the non-neuronal cholinergic system in humans // Life Sci. 2003. Vol. 72. P. 2009–2012. DOI: 10.1016/s0024-3205(03)00063-8

[29] Hofer S, Eisenbach C, Lukic IK, et al. Pharmacologic cholinesterase inhibition improves survival in experimental sepsis. Crit Care Med. 2008;36(2):404–408. DOI: 10.1097/01.CCM.0B013E31816208B3

[30] Hofer S., Eisenbach C., Lukic I.K. et al. Pharmacologic cholinesterase inhibition improves survival in experimental sepsis // Crit. Care Med. 2008. Vol. 36, No. 2. P. 404–408. DOI: 10.1097/01.CCM.0B013E31816208B3

[31] Kawashima K, Fujii T. The lymphocytic cholinergic system and its contribution to the regulation of immune activity. Life Sci. 2003;74(6):675–696. DOI: 10.1016/j.lfs.2003.09.037

[32] Kawashima K., Fujii T. The lymphocytic cholinergic system and its contribution to the regulation of immune activity // Life Sci. 2003. Vol. 74, No. 6. P. 675–696. DOI: 10.1016/j.lfs.2003.09.037

[33] Kozlova DI, Popov AV, Vasilyev DS, et al. Blood plasma pseudocholinesterase as a potential biomarker of autoimmune diseases. Russian Journal of Bioorganic Chemistry. 2018;44(2):173–177. DOI: 10.1134/S106816201802005X

[34] Козлова Д.И., Попов А.В., Васильев Д.С. и др. Псевдохолинэстераза плазмы крови как перспективный биомаркер аутоиммунных заболеваний // Биоорганическая химия. 2018. Т. 44, № 2. С. 158–162. DOI: 10.1134/S106816201802005X

[35] Darvesh S, LeBlanc AM, Macdonald IR, et al. Butyrylcholinesterase activity in multiple sclerosis neuropathology. Chem Biol Interact. 2010;187(1–3):425–431. DOI: 10.1016/j.cbi.2010.01.037

[36] Darvesh S., LeBlanc A.M., Macdonald I.R. et al. Butyrylcholinesterase activity in multiple sclerosis neuropathology // Chem. Biol. Interact. 2010. Vol. 187, No. (1–3). P. 425–431. DOI: 10.1016/j.cbi.2010.01.037

RIGHTS & PERMISSIONS

Eco-Vector